The deal includes a drug approved in the U.S. and the EU for systemic mastocytosis, a rare immunology disease, as well as an early-stage immunology pipeline, the companies said.

The acquisition includes a rare immunology disease medicine and an advanced and early-stage immunology pipeline.

Blueprint, based in Cambridge, has an approved drug called Ayvakit that treats a rare immunological condition.